Eligibility focused on p16-negative/HPV-unrelated, PD-L1 ≥1% recurrent/metastatic HNSCC recurring ≥6 months after curative-intent platinum, reflecting a high ...
The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.
LONDON--(BUSINESS WIRE)--Origami Risk, the industry-leading risk, safety, and insurance Software as a Service (SaaS) technology firm, announced the expansion of its operations in the UK and EMEA with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results